Home/Filings/4/0000950170-25-032794
4//SEC Filing

Crombez Eric 4

Accession 0000950170-25-032794

CIK 0001515673other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 8:16 PM ET

Size

11.2 KB

Accession

0000950170-25-032794

Insider Transaction Report

Form 4
Period: 2025-03-01
Crombez Eric
EVP and Chief Medical Officer
Transactions
  • Award

    Common Stock

    2025-03-01+16,81365,244 total
  • Award

    Stock Ooption (Right to Buy)

    2025-03-01+30,24630,246 total
    Exercise: $42.92Exp: 2035-03-01Common Stock (30,246 underlying)
  • Award

    Common Stock

    2025-03-01+14,97180,215 total
  • Sale

    Common Stock

    2025-03-03$42.10/sh8,945$376,58571,922 total
Footnotes (7)
  • [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
  • [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
  • [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
  • [F6]Includes 652 shares acquired on April 30, 2024 and October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan
  • [F7]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Documents

1 file

Issuer

Ultragenyx Pharmaceutical Inc.

CIK 0001515673

Entity typeother

Related Parties

1
  • filerCIK 0001653052

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:16 PM ET
Size
11.2 KB